Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Data from Baylor College of Medicine, College of Medicine advance knowledge in immunization
November 26th, 2008
"Dose-sparing strategies are being explored for vaccines against pandemic influenza. We evaluated the dose-sparing potential of aluminum hydroxide (AlOH) adjuvant," investigators in the United States report. "A total of 600 healthy subjects (age, 18-49 years) were randomized to receive 2 vaccinations 1 month apart with subvirion inactivated influenza A/H5N1 vaccine containing 7.5, 15, or 45 mu g of hemagglutinin (HA), with or without 600 mu g of aluminum hydroxide (AlOH), or 3.75 mu g of HA, with or without 300 mu g of AlOH. Serum specimens were obtained for antibody assays before and 1 month after each vaccination. All formulations were safe. Injection site discomfort...
Source: Vaccine Weekly (2008-11-26)
|
